Changes in Type 2 Biomarkers After Anti-IL5 Treatment in Patients With Severe Eosinophilic Asthma
Jae-Hyuk Jang, Seong‐Dae Woo, Young‐Soo Lee, Chang Keun Kim, Yoo Seob Shin, Young‐Min Ye, Hae‐Sim Park
Abstract
= 0.007, respectively). In conclusion, changes in the serum EDN level may be a potential biomarker for monitoring eosinophilic inflammation after anti-IL5 treatment in SEA, which is affected by onset age and asthma duration.
Topics & Concepts
MedicineTECEosinophilAsthmaGastroenterologyInternal medicineExhaled nitric oxideInflammationEosinophilicImmunologyPathologyAstronomyPhysicsBronchoconstrictionIonosphereAsthma and respiratory diseasesEosinophilic EsophagitisRespiratory and Cough-Related Research